Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul 137-701, South Korea.
J Crit Care. 2012 Dec;27(6):739.e1-6. doi: 10.1016/j.jcrc.2012.07.014.
Despite an improvement in the prognosis of patients with hematologic malignancies, the mortality of such patients transferred to the intensive care unit (ICU) is high. This study determined the predictors of mortality in a cohort of critically ill patients with hematologic malignancies admitted to the ICU.
We studied 227 critically ill patients with hematologic malignancies who were admitted to the ICU between April 2009 and December 2011. A cohort of consecutive patients with hematologic malignancies was reviewed retrospectively to identify clinically useful prognostic factors.
The ICU mortality rate was 84.1%, and the in-hospital mortality rate was 89.9%. The ICU mortality was significantly higher in patients with acute leukemia than in those with other malignancies. A significant difference between survivors and nonsurvivors was found in neutropenia and its recovery during the ICU stay, presence of cardiac dysfunction, the need for an invasive mechanical ventilator, use of inotropic/vasopressor agents, platelet count, aspartate transaminase level, pH, and Acute Physiology And Chronic Health Evaluation II score. In the multivariate analysis, acute leukemia, need for invasive mechanical ventilator, use of inotropic/vasopressor agents, and Acute Physiology And Chronic Health Evaluation II scores were independently associated with a worse outcome in patients with hematologic malignancies admitted to the ICU.
Higher mortality in patients with hematologic malignancies admitted to the ICU is associated with more severe illness, as reflected by higher organ failure scores or respiratory or hemodynamic instability. Mortality is higher in patients with acute leukemia as compared with other hematologic malignancies.
尽管血液恶性肿瘤患者的预后有所改善,但转入重症监护病房(ICU)的此类患者的死亡率仍然很高。本研究旨在确定 ICU 收治的血液恶性肿瘤危重症患者的死亡率预测因素。
我们研究了 2009 年 4 月至 2011 年 12 月期间 ICU 收治的 227 例血液恶性肿瘤危重症患者。回顾性分析连续收治的血液恶性肿瘤患者队列,以确定具有临床意义的预后因素。
ICU 死亡率为 84.1%,住院死亡率为 89.9%。与其他恶性肿瘤患者相比,急性白血病患者的 ICU 死亡率明显更高。存活组与非存活组之间在中性粒细胞减少症及其在 ICU 期间的恢复、心功能障碍、需要有创机械通气、使用正性肌力/血管加压药物、血小板计数、天门冬氨酸转氨酶水平、pH 值和急性生理学和慢性健康评估 II 评分方面存在显著差异。多变量分析显示,急性白血病、需要有创机械通气、使用正性肌力/血管加压药物和急性生理学和慢性健康评估 II 评分是 ICU 收治的血液恶性肿瘤患者预后不良的独立相关因素。
ICU 收治的血液恶性肿瘤患者死亡率较高与更严重的疾病相关,反映为更高的器官衰竭评分或呼吸或血流动力学不稳定。与其他血液恶性肿瘤相比,急性白血病患者的死亡率更高。